Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder I. Effects of different dosing regimens

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 4, 2006, Pages 416-431

  Teicher, Martin H ^a,b   Polcari, Ann ^b   Foley, Mary ^b   Valente, Elizabeth ^b   McGreenery, Cynthia E ^b   Chang, Wei Wei ^c   McKay, Gordon ^d   Midha, Kamal K ^d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c NuTeC Incorporated   (United States)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMETHYLPHENIDATE; LACTOSE; LONG ACTING DRUG; METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; BODY MOVEMENT; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MCLEAN MOTION ATTENTION TEST; PARALLEL DESIGN; PHARMACODYNAMICS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PULSATILE DRUG RELEASE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TASK PERFORMANCE;

ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHYLPHENIDATE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PULSE THERAPY, DRUG; STEREOISOMERISM;

EID: 33750601421     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.416     Document Type: Article

References (38)

1. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC, American Psychiatric Press, 1994.
2. Anderson CM, Kaufman MJ, Lowen SB, Rohan M, Renshaw PF, Teicher MH: Brain T2 relaxation times correlate with regional cerebral blood volume. Magma 18:3-6, 2005.
3. Aoyama T, Kotaki H, Iga T: Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J Pharmacobiodyn 13:647-652, 1990.
4. Aoyama T, Kotaki H, Sasaki T, Sawada Y, Honda Y, Iga T: Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur J Clin Pharmacol 44:79-84, 1993.
5. Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W: Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 72:56-59, 1983.
6. Connors CK: Symptom patterns in hyperkinetic, neurotic, and normal children. Child Dev 41:667-682, 1970.
7. Glavin GB, Dugani AM: Effects of dopamine agonists and antagonists on gastric acid secretion and stress responses in rats. Life Sci 41:1397-1408, 1987.
8. Greiff JM, Rowbotham D: Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 27:447-461, 1994.
9. Hernandez DE, Adcock JW, Orlando RC, Patrick KS, Nemeroff CB, Prange AJ, Jr.: Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. Life Sci 35:2453-2458, 1984.
10. Hubbard JW, Srinivas NR, Quinn D, Midha KK: Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J Pharm Sci 78:944-947, 1989.
11. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L: Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57:229-238, 2005.
12. Matter K, Halperin JM, Sharma V, Newcorn JH, Sathaye N: Methylphenidate response in aggressive and nonaggressive ADHD children: distinctions on laboratory measures of symptoms. J Am Acad Child Adolesc Psychiatry 31:219-225, 1992.
13. McCulloch CE, Searle SR: Generalized, linear and mixed models. New York, John Wiley & Sons, 2001.
14. Midha KK, McKay G, Rawson MJ, Korchinski ED, Hubbard JW: Effects of food on the pharmacokinetics of methylphenidate. Pharm Res 18:1185-1189, 2001.
15. Modi NB, Wang B, Hu WT, Gupta SK: Effect of food on the pharmacokinetics of osmotic controlled-released methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 21:23-31, 2000.
16. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073-1086, 1999.
17. Nuechterlein KH: Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J Abnorm Psychol 92:4-28, 1983.
18. O'Toole K, Abramowitz A, Morris R, Dulcan M: Effects of methylphenidate on attention and nonverbal learning in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36:531-583, 1997.
19. Orvaschel H, Puig-Antich J. Schedule for Affective Disorder and Schizophrenia for School-Age Children, Epidemiologic Version, Fifth Revision. Fort Lauderdale (Florida), Nova Southeastern University, 1994.
20. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107: E105, 2001.
21. Shader RI, Harmatz JS, Oesterheld JR, Parmelee DX, Sallee FR, Greenblatt DJ: Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. J Clin Pharmacol 39:775-785, 1999.
22. Spalletta G, Pasini A, Pau F, Guido G, Menghini L, Caltagirone C: Prefrontal blood flow dysregulation in drug naive ADHD children without structural abnormalities. J Neural Transm 108:1203-1216, 2001.
23. Srinivas NR, Hubbard JW, Korchinski ED, Midha KK: Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res 10:14-21, 1993.
24. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha KK: Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuropsychopharmacol Biol Psychiatry 15:213-220, 1991.
25. Srinivas NR, Hubbard JW, Quinn D, Midha KK: Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 52:561-568, 1992.
26. Srinivas NR, Quinn D, Hubbard JW, Midha KK: Stereoselective disposition of methylphenidate in children with attention-deficit disorder. J Pharmacol Exp Ther 241:300-306, 1987.
27. Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S: Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295-305, 1999.
28. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S: Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204-211, 2003.
29. Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S: Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: Effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 41:1306-1314, 2002.
30. Swanson JM, Volkow ND: Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res 130:73-78, 2002.
31. Swanson JM, Volkow ND: Serum and brain concentrations of methylphenidate: Implications for use and abuse. Neurosci Biobehav Rev 27:615-621, 2003.
32. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113:e206-e216, 2004.
33. Teicher MH: Actigraphy and motion analysis: New tools for psychiatry. Harv Rev Psychiatry 3:18-35, 1995.
34. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF: Functional deficits in basal ganglia of children with attention-deficit/ hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nature Med 6:470-473, 2000.
35. Teicher MH, Ito Y, Glod CA, Barber NI: Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry 35:334-342, 1996.
36. Teicher MH, Lowen SB, Polcari A, Foley M, McGreenery CE: Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. J Child Adolesc Psychopharmacol 14:219-232, 2004.
37. Teo SK, Scheffler MR, Wu A, Stirling DI, Thomas SD, Stypinski D, Khetani VD: A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. J Clin Pharmacol 44:173-178, 2004.
38. Wolraich ML, Doffing MA: Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 18:243-250, 2004.